Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) and Forest Laboratories, Inc. (NYSE:FRX) announced today they will present linaclotide-related data during Digestive Disease Week ® 2014 in Chicago, May 3 through May 6, 2014. The data will be presented through the following poster presentations: Clinical Posters Efficacy and Safety of Linaclotide in Chronic Idiopathic Constipation Patients With Abdominal Bloating: Phase 3b Trial Results (abstract #Sa2008) on Saturday, May 3, 2014, 8 a.m. – 5 p.m. in the South Hall, presented by Brian Lacy, M.D., Ph.D., Section Chief, Gastroenterology and Hepatology, Associate Professor of Medicine, Geisel School of Medicine, Dartmouth-Hitchcock Medical Center. The Relationship Between Chronic Constipation Symptoms and Health-Related Quality of Life: Results From 2 Phase 3 Trials (abstract #Sa1076) on Saturday, May 3, 2014, 8 a.m. – 5 p.m. in the South Hall, presented by Doug Taylor, Director, Health Economics & Outcomes Research, Ironwood Pharmaceuticals, Inc. Preclinical Posters Extracellular Cyclic GMP (cGMP), the Downstream Mediator Released in Response to Linaclotide-Induced Activation of Guanylate Cyclase-C (GC-C), Reduces Excitability of Murine and Human Dorsal Root Ganglion (DRG) Neurons (abstract #Mo2029) on Monday, May 5, 2014, 8 a.m. – 5 p.m. in the South Hall, presented by Stuart Brierley, Ph.D., NHMRC Career Development Fellow and Head of the Visceral Pain Research Group, Nerve-Gut Research Laboratory, Discipline of Medicine at the University of Adelaide. Distinct Alterations in the Guanylate Cyclase-C (GC-C)/cyclic GMP (cGMP) Pathway Are Evident Across Different Subtypes of Irritable Bowel Syndrome (IBS) Patients (abstract #Su2066) on Sunday, May 4, 2014, 8 a.m. – 5 p.m. in the South Hall, also presented by Dr. Brierley. Linaclotide Induces Endocytosis of the Sodium/Hydrogen Exchanger 3 (NHE3) and Inhibits Sodium Absorption (abstract #Mo1752) on Monday, May 5, 2014, 8 a.m. – 5 p.m. in the South Hall, presented by Nadia Ameen, MBBS, Associate Professor of Pediatrics (Gastroenterology) and of Cellular and Molecular Physiology at Yale School of Medicine. Health Economic & Outcomes Research Poster Irritable Bowel Syndrome With Constipation (IBS-C), Chronic Idiopathic Constipation (CIC), Functional Dyspepsia (FD), and Gastroesophageal Reflux Disease (GERD) Commonly Overlap: Results of a Cross-Sectional Population-Based Survey (abstract #Sa1065) on Saturday, May 3, 2014, 8 a.m. – 5 p.m. in the South Hall, presented by Nimish Vakil, M.D., Clinical Professor of Medicine at the University of Wisconsin School of Medicine and Public Health. About Linaclotide Linaclotide is a guanylate cyclase‐C (GC‐C) agonist that is thought to work in two ways based on nonclinical studies. Linaclotide binds to the GC-C receptor locally, within the intestinal epithelium. Activation of GC-C results in increased intestinal fluid secretion and accelerated transit and a decrease in the activity of pain-sensing nerves in the intestine. The clinical relevance of the effect on pain fibers, which is based on nonclinical studies, has not been established. Linaclotide is marketed by Ironwood and Forest in the United States as LINZESS ® and is indicated for the treatment of adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). Linaclotide is marketed by Almirall, S.A. for the treatment of adults with moderate to severe IBS-C in Europe under the brand name CONSTELLA®. Ironwood also has partnered with Astellas Pharma Inc. for development and commercialization of linaclotide in Japan and with AstraZeneca for development and commercialization in China. LINZESS® and CONSTELLA® are trademarks owned by Ironwood Pharmaceuticals, Inc. Any other trademarks referred to in this press release are the property of their respective owners. All rights reserved.